Xilio Therapeutics, Inc. (XLO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -22.34M | -2M | -17.5M | -14.48M | 28.98M | -14.16M | -13.67M | 19.95M | -10.5M | -13.43M | -13.37M | -16.57M |
| Operating CF Margin % | -176.65% | -14.6% | -91.76% | -179.08% | 989.01% | -821.17% | -604.15% | 846.54% | - | - | - | - |
| Operating CF Growth % | -177.1% | 85.89% | -27.96% | -172.56% | 375.93% | -5.44% | -2.27% | 220.39% | 58.41% | 26.32% | 32.85% | 1.09% |
| Net Income | -9.53M | 10.36M | -16.29M | -15.84M | -13.27M | -13.09M | -14.02M | -13.93M | -17.2M | -17.66M | -16.75M | -19.36M |
| Depreciation & Amortization | 344K | 323K | 340K | 381K | 497K | 375K | 381K | 445K | 443K | 449K | 460K | 492K |
| Stock-Based Compensation | 0 | 2.93M | 0 | 1.35M | 1.53M | 1.52M | 1.57M | 1.51M | 1.83M | 0 | 1.86M | 1.8M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.09M | -21.27M | 16.5M | 2.33M | 0 | 2K | 34.74M | 0 | 0 | 1.95M | 24K | 89K |
| Working Capital Changes | -12.07M | 5.66M | -18.05M | -2.7M | 40.21M | -2.96M | -36.35M | 31.92M | 4.42M | 1.83M | 1.03M | 400K |
| Change in Receivables | 5M | 12.5M | 0 | 0 | 0 | 0 | 0 | 0 | -30M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.68M | 428K | -1.8M | 2.11M | -590K | 1.6M | -281K | 509K | -305K | -438K | 542K | -809K |
| Cash from Investing | -556K | -95K | 0 | -401K | -22K | -6K | -9K | -21K | 0 | 0 | 0 | -316K |
| Capital Expenditures | -556K | -95K | 0 | -401K | -22K | -6K | -9K | -21K | 0 | 0 | 0 | -316K |
| CapEx % of Revenue | 4.4% | 0.69% | - | 4.96% | 0.75% | 0.35% | 0.4% | 0.89% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 35.71M | 35.87M | -285K | 47.36M | 4.83M | 8.2M | -3K | 20.04M | 954K | -1.63M | -2.24M | -992K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 3.38M | -7K | -21K | -3.35M | -1.69M | -2.24M | -1.13M |
| Equity Issued (Net) | 37.26M | 35.87M | -285K | 47.32M | 4.83M | 1K | 4K | 2.52M | 4.31M | 54K | 8K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.55M | 0 | 0 | 44K | 5K | 4.82M | 0 | 17.55M | 0 | 0 | 0 | 140K |
| Net Change in Cash | 12.8M | 33.77M | -17.79M | 32.48M | 33.79M | -5.96M | -13.68M | 39.98M | -9.55M | -15.07M | -15.61M | -17.88M |
| Free Cash Flow | -22.9M | -2.09M | -17.5M | -14.88M | 28.96M | -14.16M | -13.68M | 19.93M | -10.5M | -13.43M | -13.37M | -16.89M |
| FCF Margin % | -181.05% | -15.29% | -91.76% | -184.04% | 988.26% | -821.52% | -604.55% | 845.65% | - | - | - | - |
| FCF Growth % | -179.08% | 85.22% | -27.88% | -174.64% | 375.72% | -5.48% | -2.33% | 218.01% | 58.69% | 28.32% | 33.95% | 3.63% |
| FCF per Share | -0.14 | -0.03 | -1.70 | -4.02 | 5.43 | -3.07 | -3.02 | 6.35 | -5.27 | -6.82 | -6.80 | -8.61 |
| FCF Conversion (FCF/Net Income) | 2.34x | -0.19x | 1.07x | 0.91x | -2.18x | 1.08x | 0.98x | -1.43x | 0.61x | 0.76x | 0.80x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62K | 0 | 0 | 123K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |